Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeResource RepositorySITC 2026: Immune Mechanisms, Core Targets & Emerging Therapies
Trends & Analysis

SITC 2026: Immune Mechanisms, Core Targets & Emerging Therapies

This report analyzes the 41st SITC Annual Meeting (2026), covering 1,065 regular abstracts, 42 award abstracts and 19 late-breaking abstracts. Key signals include tumor-localized conditional activation, costimulation-enhanced T-cell engagers, the PD-1×VEGF bispecific race, in vivo cell engineering and biparatopic ADCs, with competitive hotspots across PD-1/PD-L1, CD3, VEGF, GPC3, STEAP2, PSMA, KRAS and IL-12.
SITC 2026: Immune Mechanisms, Core Targets & Emerging Therapies

Overview

Based on SITC 2026 public abstracts and the JITC supplements, this report provides a structured view of immuno-oncology innovation, moving from conference-level statistics to late-breaking clinical evidence and then to a modality-by-modality target analysis. It covers mAbs and multispecifics, T-cell engagers, CAR platforms, ADCs, TCR-T and cytokine-based therapies, and tracks the shared design logic emerging across them: localizing activity to the tumor, recruiting non-conventional effector cells, and broadening antigen recognition while controlling systemic toxicity. With most studies still preclinical or early clinical, the report also flags where evidence maturity, trial design and population differences limit cross-study comparison, offering reference value for target prioritization, preclinical model selection and BD assessment.

Key Insights

Selected SITC 2026 abstracts covering immune mechanisms, therapeutic modalities, target landscapes and clinical translation.
  • Key innovation areas: costimulation-enhanced and conditionally activated T-cell engagers, PD-1×VEGF bispecifics, in vivo CAR-T/CAR-M/CAR-B/CAR-Treg and in vivo TCR-T, biparatopic and immune-cell-directed ADCs, therapeutic vaccines, allogeneic NK and intratumoral siRNA.
  • Major focus targets: PD-1/PD-L1, CD3, CD28/4-1BB/CD2 costimulation, VEGF, GPC3, STEAP2, PSMA, KLK2, B7-H3, MSLN, KRAS, TREM2, OX40, BTN1A1/BTN3A, IL-18BP and IL-12/IL-27, with activity concentrated in NSCLC, prostate cancer, HCC, melanoma, breast cancer and multiple myeloma.
  • Emerging trend: engineering is moving inside the body, as mRNA-LNP and targeted viral delivery turn cell therapy into an in vivo process, while conditional activation and local delivery decouple antitumor activity from systemic exposure.
  • Strategic value: supports target prioritization, humanized and tumor model selection for preclinical validation, and early assessment of competitive and licensing opportunities in immuno-oncology.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Download Details
Full Name
Email
Organization
Job Role
Country
Main Area of Research
Resource Preferences
Which type of solutions are you considering?
Do you plan to start a project with us within the next 6 months?
How did you hear about us?
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research